European Commission approves Erbitux combination for first-line BRAF V600E-mutant mCRC

Servier acquires Edgewise Therapeutics' muscular dystrophy business

Eisai reports new data showing etalanetug reduces Alzheimer's Disease tau tangle‑specific biomarker

Takeda and Indonesia launch partnership to expand plasma-derived medicine production

HDT Bio Launches Canadian clinical programme for brain cancer treatment

Antengene receives USD60m upfront payment from UCB

BioArctic's partner Eisai presents new clinical data on Leqembi subcutaneous autoinjector at AAIC 2026

FDA approves Sanofi's subcutaneous Sarclisa Escena as first anticancer therapy delivered via on-body injector

Nexstim expands Health Canada approval for NBS 6

Biohaven announces scientific leadership changes

DIA and MHRA plan global regulatory science summit in London

MetaVia completes DA-1726 dose titration in Phase 1 Part 3 study for obesity treatment

Ipsen reports positive Phase III results for Dysport in episodic and chronic migraine

Ionis and AstraZeneca's eplontersen Phase 3 ATTR-CM trial misses primary endpoint, subgroup analysis shows nominal benefit

Altruist Biologics' Hangzhou ADC facility approved for segmented production